After playing a critical role in curbing COVID-19 disease with its vaccine, Pfizer and CEO Albert Bourla late last year introduced an oral antiviral therapy to treat those at highest risk of severe illness. The two-drug combination is the first pill-based coronavirus treatment in the U.S., and can reduce the risk of hospitalization or death by up to 89%. Demand for Paxlovid, which has received emergency-use authorization from the U.S. Food and Drug Administration, will likely increase under the White House’s plan to broaden access to such therapies with its Test to Treat initiative.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief
More Must-Reads from TIME
- How Kamala Harris Knocked Donald Trump Off Course
- Introducing TIME's 2024 Latino Leaders
- George Lopez Is Transforming Narratives With Comedy
- How to Make an Argument That’s Actually Persuasive
- What Makes a Friendship Last Forever?
- 33 True Crime Documentaries That Shaped the Genre
- Why Gut Health Issues Are More Common in Women
- The 100 Most Influential People in AI 2024